Novartis’s psoriasis drug Cosentyx showed long-term efficacy in keeping patients’ skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.
More than 66 per cent of Cosentyx patients achieved “clear or almost clear” skin after four years, Novartis said, comparable with the 68.5 per cent who hit that milestone after one year. A durable response is important, since older biotech drugs for plaque psoriasis, known as anti-TNFs, can lose their effectiveness over time.
Cosentyx’s second-quarter sales hit $260 million from $30 million in the second quarter of 2015, just after it went on sale, largely as it won patients from anti-TNFs such as Amgen’s Enbrel. With Novartis aiming for $5 billion in peak annual revenue, the company is now pushing for more dermatologists to shift patients to Cosentyx from Johnson & Johnson’s Stelara.
- Mumbai Call Centre Scam: All You Need To Know
- Jammu Kashmir Chief Minister Mehbooba Mufti Appeals To Police: Here’s What She Said
- Shocker From Ahmedabad: Find Out What Happened
- Bigg Boss 10 Day 3 Review: Celebs Fail To Do Well in First Task
- Airtel Offers 10GB Data At Rs 259 For New 4G Smartphone Users
- Aamir Khan Starrer Dangal’s Trailer Launched: First Impressions
- TMC Supporters Attack BJP Leader Babul Supriyo
- Sri Lankan Navy Apprehends 20 Indian Fishermen
- Hillary Clinton accuses Donald Trump of being Vladimir Putin’s ‘puppet’
- Senior UP Congress Leader Rita Bahuguna Joshi Joins BJP
- Missing JNU Student: VC Gives Ultimatum To Students Over ‘Illegal Confinement’
- US Presidential Debate: Donald Trump Calls Hillary Clinton ‘A Nasty Woman’
- Hasselblad True Zoom Mod Review
- Honor 8 First Look Video
- Apple Watch 2: Review, Price And Features
“Our focus has been continuing to generate the data and convince physicians that it’s worth making the switch,” said Vasant Narasimhan, Novartis chief medical officer, in an interview ahead of a dermatology congress in Vienna. “Now you have data out to four years showing we’ve maintained the efficacy, at the levels that we saw after year one,” Narasimhan said.
Novartis’s findings released on Saturday also showed Cosentyx helped 60 per cent of people with psoriasis on their hands and feet achieve clear or nearly clear skin on these difficult-to-treat areas.
Since its introduction in early 2015, Cosentyx has won EU and U.S. approval for psoriasis as well as for active ankylosing spondolitis and psoriatic arthritis, a painful autoimmune condition that damages joints and to which many psoriasis patients are vulnerable.